Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 21:30:00 03/05/2024 BST 5-day change 1st Jan Change
125 USD -0.47% Intraday chart for Moderna, Inc. +17.72% +25.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jefferies Adjusts Price Target on Moderna to $155 From $125 MT
Oppenheimer Adjusts Price Target on Moderna to $163 From $142 MT
Goldman Sachs Adjusts Price Target on Moderna to $204 From $206 MT
Leerink Adjusts Price Target on Moderna to $60 From $59 MT
Morgan Stanley Adjusts Price Target on Moderna to $95 From $89 MT
Jefferies & Co Adjusts Moderna Price Target to $155 From $125 MT
Goldman Sachs Adjusts Moderna Price Target to $204 From $206 MT
Morgan Stanley Raises Price Target on Moderna to $95 From $89, Keeps Equalweight Rating MT
RBC Raises Price Target on Moderna to $135 From $125 on 'More Prudent Financial Outlook,' Keeps Outperform Rating MT
ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna... Our Logo
MODERNA : price target raised by Oddo BHF CF
Wall Street: optimism ahead of NFP, rates ease CF
Wall Street: optimism ahead of NFP, rates ease CF
Equity Markets Close Higher Ahead of Jobs Report MT
Health Care Flat Amid Mixed Earnings -- Health Care Roundup DJ
Equity Markets Close Higher Ahead of Jobs Report MT
Sector Update: Health Care Stocks Softer Late Afternoon MT
Equity Markets Higher Ahead of Apple Earnings MT
S&P 500, Nasdaq Rise Intraday Amid Moderna Rally as Traders Await Apple Results MT
Sector Update: Health Care Stocks Retreat Thursday Afternoon MT
RBC Raises Price Target on Moderna to $135 From $125 MT
Sector Update: Health Care MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple... Our Logo
News Highlights : Top Company News of the Day - Thursday at 11 AM ET DJ
Moderna Maintains Full-Year Sales Guidance Following First-Quarter Beat MT
Chart Moderna, Inc.
More charts
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
125.6 USD
Average target price
139.3 USD
Spread / Average Target
+10.90%
Consensus
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. News Moderna, Inc.
  5. Moderna New Omicron Boosters Show Stronger Response, Indicate Neutralizing Activity Against Emerging Variant